Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199120 | 1.00 | LTB4R (0.34) | LTB4RLTB4R2CES2CES1FFAR3 | |
| SCHEMBL15482472 | 0.78 | ALDH1A1 (0.38) | CES2CES1FFAR3HDAC3HDAC1 | |
| SCHEMBL9317697 | 0.72 | — | — | |
| SCHEMBL9317701 | 0.72 | — | — | |
| SCHEMBL17469184 | 0.72 | CES1 (0.35) | CES2CES1KDM1AALDH1A1POLB | |
| SCHEMBL22159652 | 0.71 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL2035630 | 0.70 | CES2 (0.41) | CES2CES1FFAR3HDAC3HDAC1 | |
| SCHEMBL11152978 | 0.70 | CES1 (0.41) | CES2CES1FFAR3HDAC3HDAC1 | |
| SCHEMBL11152980 | 0.70 | CES1 (0.41) | CES2CES1FFAR3HDAC3HDAC1 | |
| SCHEMBL2152750 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8075937-B2 | Alkyldienamides exhibiting taste and sensory effect in flavor compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090311402-A1 | ALKYLDIENAMIDES EXHIBITING TASTE AND SENSORY EFFECT IN FLAVOR COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2009-12-17 | — | — | US | disclosed |
| US-7632531-B2 | Alkyldienamides exhibiting taste and sensory effect in flavor compositions | International Flavors & Fragnances Inc. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1473287-B1 | Alkyldienamides exhibiting taste and sensory effect in flavor compositions | INT FLAVORS & FRAGRANCES INC (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1473287-A2 | Alkyldienamides exhibiting taste and sensory effect in flavor compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040202619-A1 | Alkyldienamides exhibiting taste and sensory effect in flavor compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202619-A1 | Alkyldienamides exhibiting taste and sensory effect in flavor compositions | TAS2R5, TAS2R4, TAS2R3 | LTB4R 1563/4885LTB4R2 1066/4885CES2 1386/4885 |
| US-20090311402-A1 | ALKYLDIENAMIDES EXHIBITING TASTE AND SENSORY EFFECT IN FLAVOR COMPOSITIONS | TAS2R5, TAS2R45, TAS2R16 | LTB4R 1689/4885LTB4R2 1754/4885CES2 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.